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S Nonen17, MK Skime1, L Wang12, BT Baune18, M Kato14, YL Liu19, V Praphanphoj20, JC Stingl21, SJ Tsai9,10, M Kubo16, TE Klein3 and
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Response to treatment with selective serotonin reuptake inhibitors (SSRIs) varies considerably between patients. The International
SSRI Pharmacogenomics Consortium (ISPC) was formed with the primary goal of identifying genetic variation that may contribute
to response to SSRI treatment of major depressive disorder. A genome-wide association study of 4-week treatment outcomes,
measured using the 17-item Hamilton Rating Scale for Depression (HRSD-17), was performed using data from 865 subjects from
seven sites. The primary outcomes were percent change in HRSD-17 score and response, defined as at least 50% reduction in
HRSD-17. Data from two prior studies, the Pharmacogenomics Research Network Antidepressant Medication Pharmacogenomics
Study (PGRN-AMPS) and the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, were used for replication,
and a meta-analysis of the three studies was performed (N= 2394). Although many top association signals in the ISPC analysis map
to interesting candidate genes, none were significant at the genome-wide level and the associations were not replicated using
PGRN-AMPS and STAR*D data. Top association results in the meta-analysis of response included single-nucleotide polymorphisms
(SNPs) in the HPRTP4 (hypoxanthine phosphoribosyltransferase pseudogene 4)/VSTM5 (V-set and transmembrane domain
containing 5) region, which approached genome-wide significance (P= 5.03E− 08) and SNPs 5’ upstream of the neuregulin-1 gene,
NRG1 (P= 1.20E− 06). NRG1 is involved in many aspects of brain development, including neuronal maturation and variations in this
gene have been shown to be associated with increased risk for mental disorders, particularly schizophrenia. Replication and
functional studies of these findings are warranted.
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INTRODUCTION
Major depressive disorder (MDD) is a serious psychiatric illness
with a lifetime prevalence of ~ 13%.1 While several types of
antidepressant medications have been shown to have beneficial
effects for MDD symptoms, selection of the most appropriate
medication for individual patients continues to be a challenge.
Selective serotonin reuptake inhibitors (SSRIs) are the most
commonly used medication class for MDD;2,3 however, response
to SSRI treatment varies considerably between patients, and it is
widely recognized that identification of pharmacogenetic pre-
dictors of drug response has great potential to improve the
treatment of MDD.4
Several genome-wide association studies (GWAS) of SSRI
treatment outcomes have been performed.5–9 None of these
studies have identified genetic variants that were associated with
treatment outcomes at a genome-wide statistically significant
level. Moreover, top findings from these studies have not been
replicated in independent samples. Nevertheless, analysis of
antidepressant response data using a mixed linear model
approach to estimate the proportion of phenotypic variance
explained by genome-wide single-nucleotide polymorphisms
(SNPs, the GREML approach) implemented in the Genome-Wide
Complex Trait Analysis package10 has demonstrated that common
genetic variants explain a considerable proportion of individual
differences in antidepressant response,11 providing compelling
motivation for further pharmacogenomic studies.
Prior pharmacogenomic studies of antidepressant response
have shown that GWAS have low power for discovery of relevant
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variants for this highly complex trait. Thus, large samples, such as
those arising from the formation of collaborative consortia, will be
necessary to make further progress in this field.12,13 Taking this
approach, Tansey et al.13 described a pharmacogenomic analysis
of data arising from the NEWMEDS consortium, which includes
response to serotonergic and noradrenergic antidepressants in
over 2000 European-ancestry individuals with MDD. The analyses,
which also included a meta-analysis with data from the
Sequenced Treatment Alternatives to Relieve Depression (STAR*D)
study,14 did not identify any common genetic variants associated
with antidepressant response at a genome-wide significant level.
Another recent meta-analysis combined the results of three prior
studies to search for genetic variation associated with remission
following treatment with antidepressants, and with SSRIs (escita-
lopram or citalopram) specifically.12 These analyses failed to
replicate the single-study results in the pooled analysis. However,
the analysis of the entire sample (all antidepressants) resulted in
one genome-wide significant association of a SNP located in an
intronic region of the myosin X (MYO10) gene. The analysis of the
SSRI-treated subset revealed an association between early SSRI
response (within 2 weeks of treatment) and a SNP in an intergenic
region on chromosome 5.
The International SSRI Pharmacogenomics Consortium (ISPC)
was established to investigate the genetic factors contributing to
variable response to SSRIs. Because a variety of SSRIs were used in
the studies contributed to the consortium, this sample provides
the opportunity to identify genes that contribute to the
pharmacodynamic, though not pharmacokinetic, effects of these
medications. This is the first report of findings from a GWAS of
SSRI treatment response based on the ISPC sample. Data from two
prior GWAS of SSRI response, the Mayo Clinic Pharmacogenomic
Research Network Antidepressant Medication Pharmacogenomics
Study (PGRN-AMPS)7,15 and the STAR*D study,14 were used for
replication analysis, and a meta-analysis of the three studies was
performed.
MATERIALS AND METHODS
Study design and samples
The ISPC initially included eight member sites (Supplementary Table S1),
with one site subsequently excluded because of unavailable clinical data.
The seven studies included in the analyses represent five countries from
Europe, North America and Asia, with 2/3 of the sample being Asian
(Taiwan, Thailand and Japan) and 1/3 being of European descent (Germany
and the United States). All sites included in analyses had approval to
participate in the consortium from their local ethical review board.
In total, 1149 DNA samples and clinical data for 998 subjects were
contributed. Demographic and clinical data provided by individual sites
were curated (that is, collected, formatted and subjected to quality control)
by staff at the Pharmacogenetics and Pharmacogenomics Knowledge Base
(PharmGKB, www.pharmgkb.org). Supplementary Table S2 lists the
collected data, which included information on factors previously shown
to be associated with antidepressant therapy response. These data
included demographic characteristics, socioeconomic data, depression
history, co-occurring diseases, antidepressant medication, dose and
compliance, use of concomitant medications, rating scores of the
individual items of the Hamilton Rating Scale for Depression (HRSD) at
baseline and follow-up visits, side effects (if reported) and possible dose or
antidepressant change at follow-up visits. Several subjects that did not
receive SSRIs during the study period were removed from analysis.
A description of each contributing study, including the medications
used in the study, is included in Supplementary Table S1, and key features
of the samples used in the analyses are summarized in Table 1. The
pharmacogenomic analysis focused on treatment outcomes at 4 weeks, as
this time point was common to all participating studies. Prior studies have
shown that early response in depression is strongly correlated with late
response, which supports our choice of 4 weeks of observation period.16–18
However, because 4 weeks is considered too early to observe complete
remission, our analyses focused on percentage reduction in HRSD score
and response (defined as ⩾ 50% reduction in HRSD score) rather than
remission, as described in the Statistical analysis section.
Genotyping, quality control and imputation
All DNA samples (N=1149) were shipped to Mayo Clinic, Rochester, MN,
USA for storage and plating, and were genotyped at the RIKEN Center of
Integrative Medical Sciences (Yokohama, Japan) using Illumina Human-
OmniExpressExome BeadChips. Three samples failed genotyping. Quality
control assessments of the genetic data were performed as described in
the Supplementary Materials, and structure analysis19 was used to infer
ancestry using the genome-wide SNP data (Supplementary Figure S1),
leading to removal of 16 subjects (11 related, 1 gender mismatch, 4 race
outliers; see Supplementary Materials for details). As discussed in the
Supplementary Methods section, there was clear population structure
between sites, but without evidence of residual population stratification
within sites. We verified that after adjustment for site, no further
adjustment for ancestry via principal components was necessary. Thus,
because site provided a good surrogate measure for ancestry, subsequent
analyses were adjusted for site without further adjustment for population
structure. After quality control, 631 765 genotyped SNPs remained for
analysis. Genotypes at unobserved SNPs with minor allele frequency
40.01 in the reference population were imputed using Beagle (v3.3.1)20
with the 1000 genomes cosmopolitan reference panel. After removing
markers with poor imputation quality (dosage R2o0.3), ~ 7 million
imputed markers were available for analysis.
Statistical analysis
The pharmacogenomic analyses focused on treatment outcomes at
4 weeks, as this time point was common to all participating studies.
GWA analyses were performed for two phenotypes: ‘% change in HRSD-17
score’ (%ΔHRSD defined as the change in HRSD-17 score divided by the
baseline score) and ‘response’ (defined as ⩾ 50% reduction in HRSD-17
score from baseline to 4-week visit). Because response is defined by
dichotomizing %ΔHRSD, these two outcomes are highly correlated, and
therefore results of analyses of the two outcomes are also correlated.
However, the Spearman correlation of the test-statistics (or equivalent
Table 1. Demographic and clinical characteristics of the samples from individual ISPC member sites included in the genetic analysis
Characteristic Study 1a Study 2a Study 4a Study 5a Study 6a Study 7a Study 8a Total/average
Country Taiwan Taiwan Germany Germany USA Thailand Japan --
Number of subjects in GWAS 177 245 50 58 190 24 121 865
Age, mean (s.d.) 47.1 (15.2) 41.4 (13.7) 50.1 (17.1) 46.3 (13.6) 39.4 (13.6) 44.6 (10.7) 46.2 (15.4) 43.7 (14.7)
Sex, N (%) female 97 (54.8%) 201 (82.0%) 32 (64.0%) 43 (74.1%) 116 (61.1%) 15 (62.5%) 57 (47.1%) 561 (64.9%)
Baseline HRSD-17 score,
mean (s.d.)
26.4 (4.05) 21.3 (4.18) 22.6 (7.55) 24.2 (6.10) 21.0 (4.87) 15.0 (3.58) 20.0 (5.68) 22.2 (5.53)
4-Week HRSD-17 score,
mean (s.d.)
13.6 (5.33) 12.4 (5.17) 8.84 (7.90) 13.6 (7.81) 12.0 (6.05) 7.58 (6.79) 9.37 (5.73) 11.9 (6.12)
Remitters at 4 weeks, N (%) 20 (11.3%) 47 (19.2%) 26 (52.0%) 17 (29.3%) 49 (25.8%) 16 (66.7%) 51 (42.1%) 226 (26.1%)
Responders at 4 weeks, N (%) 89 (50.3%) 97 (39.6%) 34 (68.0%) 24 (41.4%) 82 (43.2%) 15 (62.5%) 75 (62.0%) 416 (48.1%)
Abbreviations: GWAS, genome-wide association study; HRSD, Hamilton Rating Scale for Depression; ISPC, International SSRI Pharmacogenomics Consortium.
aStudy numbers correspond to the contributing studies described in Supplementary Table S1.
ISPC GWAS of antidepressant response
JM Biernacka et al
2
Translational Psychiatry (2015), 1 – 9
P-values) from analyses of these two outcomes is not very high (0.50 in the
ISPC data), indicating that analyses of these two correlated outcomes can
detect associations with different SNPs. Thus, analyses of both outcomes
are presented.
The analysis included subjects with HRSD-17 data at baseline and week
4 (one entire site was removed due to missing clinical information), and
was restricted to subjects with a baseline HRSD-17 score ⩾ 10. Table 1
shows the demographic and clinical characteristics of the final sample
used for the GWA analyses (865 subjects from seven sites). Distributions of
baseline HRSD-17, sex and age differed significantly among sites. All GWA
analyses were adjusted for age and sex, in addition to site. However,
because age and sex were not statistically significant predictors of
treatment outcomes after adjustment for site, we also repeated the GWA
analyses without age and sex adjustment. The results were virtually
identical, and only the age- and sex-adjusted results are presented.
For the GWA analysis of %ΔHRSD, the association of each SNP with the
outcome was tested using a linear regression model, with the SNP (coded
as 0, 1, 2) and the covariates (age, sex and site) as independent variables
and %ΔHRSD as the dependent variable. Because the distribution of %
ΔHRSD demonstrated departures from normality, a van der Warden
transformation was applied before analysis. For the binary outcome
(response), logistic regression was used to test for SNP effects, while
accounting for the covariate effects.
Analyses were performed in R (http://www.R-project.org), SAS (SAS
Institute, Cary, NC, USA) and PLINK.21 P-values o5 × 10−8 were considered
statistically significant at the genome-wide level.
Replication of ISPC findings using PGRN-AMPS and STAR*D data
SNPs with the smallest P-values in each of the top 10 association regions in
the two primary analyses (that is, top SNP in each region) were tested for
association with equivalent outcomes in two independent samples: the
PGRN-AMPS15 and STAR*D.14 GWA analyses utilizing these two samples are
published,5,7 and both data sets are available through controlled access via
the database for Genotypes and Phenotypes (dbGaP; http://www.ncbi.nlm.
nih.gov/gap).
Both the PGRN-AMPS and STAR*D evaluated depression outcomes
following treatment with SSRIs. Although the PGRN-AMPS utilized both the
HRSD and the 16-item Quick Inventory of Depressive Symptomatology
(QIDS-C16) to measure depression symptoms at baseline and follow-up,
STAR*D used primarily QIDS-C16 during the follow-up visits. Thus,
replication analyses in the PGRN-AMPS data used the same treatment
outcome definitions as the analysis of the ISPC data (based on HRSD-17),
whereas replication analyses in the STAR*D data used equivalent %change
and response outcomes definitions based on the QIDS-C16.
Analyses of the replication samples resembled those of the ISPC sample,
using linear regression for quantitative outcomes and logistic regression
for binary outcomes. Details of the quality control analyses in PGRN-AMPS
have been described previously.7 To control for possible remaining
population structure, analyses of the predominantly Caucasian PGRN-
AMPS sample were adjusted for the first four eigenvectors derived from
genome-wide SNP data thinned on the basis of linkage disequilibrium.
After quality control filters (based on Garriock et al.,5 and removing 25
individuals from related pairs), genetic data were available for 1887
individuals from STAR*D; our analyses used data from 1529 subjects that
had both baseline and 4-week QIDS-C16 measurements. Because the
STAR*D sample included individuals of multiple ancestral backgrounds,
analyses of this sample were adjusted for the first seven eigenvectors
constructed from genome-wide SNP data, calculated in the same way as in
the PGRN-AMPS.
Meta-analyses of ISPC, PGRN-AMPS and STAR*D data
We also performed GWA analyses on the combined ISPC+AMPS sample,
followed by a fixed-effects meta-analysis to combine the ISPC+AMPS GWA
results with STAR*D GWA results (total sample size of 2394). Estimated
effect sizes from the two analyses were combined by averaging the
estimates weighted by the inverse of their variances. The combined
estimates were then tested by a two-sided Z-test using a pooled
standard error.
Replication of results from prior genome-wide meta-analyses of
antidepressant response
Finally, we used our sample to attempt replication of top findings from two
recent large GWA studies of antidepressant response.12,13 In particular, we
attempted to replicate association with two SNPs that reached genome-
wide significance in a published meta-analysis of GENDEP, MARS and
STAR*D data12 (rs17651119 in MYO10, which was associated with 12-week
percentage improvement in the entire sample, and the intergenic SNP
rs12054895 that was associated with 2-week improvement in the SSRI-
treated subset), as well as six other SNPs with suggestive evidence of
association with one of the treatment outcomes (Po1.0E− 06). Because
this meta-analysis included the STAR*D sample, we evaluated replication
of these prior findings in the ISPC sample and the combined ISPC plus
PGRN-AMPS sample, but not in our meta-analysis that included STAR*D as
that would not constitute an independent replication. We also investigated
six SNPs with Po5.0E− 06 reported by Tansey et al.13 for the overall
analysis or the analysis of subjects treated with serotonergic antidepres-
sants. For the SNPs reported by Tansey et al., we evaluated replication in
our ISPC sample, as well as in our ISPC-AMPS-STAR*D meta-analysis.
RESULTS
Out of 865 individuals with baseline and 4-week HRSD-17 scores
(baseline mean (s.d.) = 22.2 (5.5); 4-week mean (s.d.) = 11.9 (6.1)),
416 (48%) were responders (Table 1). Figure 1 shows the
Manhattan plots for the association of genotyped and imputed
SNPs with the two clinical outcomes (%ΔHRSD and response), with
the corresponding QQ plots shown in Supplementary Figure S2.
The top 10 genotyped SNP associations (smallest P-values) for
each outcome are listed in Table 2; none of these associations
reached genome-wide significance. Top results for %ΔHRSD
included SNPs in the genes MCPH1 (microcephalin 1) and STK39
(serine threonine kinase 39). Top results for response included
MCPH1, PPIAP14 (peptidylprolyl isomerase A (cyclophilin A)
pseudogene 14), SCN7A (sodium channel, type 7, alpha subunit),
BRD2 (bromodomain containing 2) and HPRTP4 (hypoxanthine
phosphoribosyltransferase pseudogene 4).
The top 10 SNP association regions including imputed SNPs are
shown in Supplementary Table S3, where for each association
region, the SNP with the smallest P-value is listed. The top
association signal in the analysis of imputed SNP data was a low
frequency SNP, rs56058016, in the von Willebrand factor A domain
containing 5B1 gene (VWA5B1) with P= 1.1E− 07 for association
with %ΔHRSD. Other new signals in the analysis of imputed SNPs,
not reaching genome-wide significance, included CTNNA3 (catenin
alpha 3) for %ΔHRSD and RYR3 (ryanodine receptor 3) for
response. None of the top associations were replicated in the
PGRN-AMPS or STAR*D analyses (Supplementary Table S3).
Replication of the top association signal in VWA5B1 could not be
tested as this SNP was not imputed with adequate quality in the
PGRN-AMPS and STAR*D data sets.
Results of the meta-analysis of the three data sets are shown in
Figure 2 (Manhattan plots), Supplementary Figure S3 (QQ plots)
and Table 3 (top 10 association SNPs for each outcome). In the
meta-analysis of response, one SNP approached genome-wide
significance (Table 3; rs2456568, P= 5.0E− 08). This SNP lies 3’
downstream of the pseudogene HPRTP4, with other SNPs in this
region with P-values o10− 6 being located 5’ upstream of the
gene VSTM5 (V-set and transmembrane domain containing 5;
Supplementary Figure S4). Other notable top association regions
for response include the 5’ upstream region of the neuregulin
gene, NRG1 (Figure 2b and Supplementary Figure S5). Top
association signals (Po1.0E− 06) for %change in depression
score include SNPs in the MTMR12 (myotubularin-related protein
12) gene (Table 3).
Supplementary Table S4 shows results in the ISPC sample and
the ISPC/PGRN-AMPS/STAR*D meta-analysis for SNPs selected on
the basis of two recent large pharmacogenomic GWAS of
antidepressant response.12,13 Although the observed associations
are not significant after correction for multiple testing of SNPs
selected for these replication analyses, we observed marginally
significant evidence of association of SNP rs11624702 in MDGA2
(MAM domain containing glycosylphosphatidylinositol anchor 2)
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Figure 1. Manhattan plots showing genome-wide association results of the two outcome variables in the ISPC data analysis: (a) %ΔHRSD (b)
response. HRSD, Hamilton Rating Scale for Depression; ISPC, International SSRI Pharmacogenomics Consortium.
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with response in the ISPC alone (P= 0.061) and in the combined
ISPC-AMPS-STAR*D meta-analysis (P= 0.029), with the minor allele
being associated with lower odds of response (that is, worse
clinical outcomes). Nominally significant association was also
found for SNP rs7174755 in ITGA11 (integrin, alpha 11) in the
combined ISPC+AMPS sample (P= 0.010 for association with %
ΔHRSD; P= 0.025 for response). We also observed nominally
significant association of the minor allele at SNP rs2546057 in
KCTD15 (potassium channel tetramerization domain containing
15) with higher odds of response (better clinical outcome) in the
ISPC sample, but this association did not remain significant in the
combined ISPC+AMPS analysis.
DISCUSSION
Genome-wide analyses of data from the ISPC presented here did
not detect SNPs significantly associated with %ΔHRSD or
response, and analyses of the PGRN-AMPS and STAR*D data did
not replicate the top association signals from the analysis of the
ISPC data. The top association signal was obtained for a set of
imputed SNPs in the VWA5B1 gene (P= 1.1E− 07). This result
should be interpreted cautiously as this is a rare imputed SNP. A
meta-analysis that included the ISPC, PGRN-AMPS and STAR*D
data revealed a SNP in the region of the HPRTP4 and VSTM5 genes
that approached genome-wide significance for association with
response (P= 5.0E− 08). Replication of this association signal is
warranted, before further functional follow-up. Moreover, several
of the top association signals that did not achieve genome-wide
significance were in genes of biological interest, most notably
NRG1, which merits further investigation into their potential role
in depression and antidepressant response.
The third highest association signal in our meta-analysis of
response locates to the promoter region of the neurotrophic
factor neuregulin-1 (NRG1) gene. Neuregulin is involved in many
aspects of brain development, including neuronal maturation, and
variations in NRG1 are associated with risk for mental disorders
including schizophrenia.22,23 In fact, the SNP with strongest
evidence of association with SSRI treatment outcomes identified
here (rs10954808) is in linkage disequilibrium with rs7014762
(r2 = 0.80 in 1000 genomes CEU sample; r2 = 0.47 in 1000 genomes
CHB/JPT sample), which was previously shown to be associated
with a bipolar phenotype characterized by excellent recovery
between episodes and no mood incongruent features.24 Another
SNP in relatively high linkage disequilibrium with rs10954808
(rs4281084, r2 = 0.85 in 1000 genomes CEU sample, r2 = 0.61 in
1000 genomes CHB/JPT sample) was reported to be associated
with transition to psychosis in at-risk individuals.25
Although NRG1 has been implicated in various psychiatric traits,
this is, to the best of our knowledge, the first human
pharmacogenomics study suggesting it may have a role in
antidepressant treatment response. NRG1-ErbB4 signaling has a
key role in the modulation of synaptic plasticity through
regulating neurotransmission, and neuregulin was suggested to
be a biomarker of MDD.26 In a recent animal model study,
subchronic peripheral neuregulin-1beta administration increased
ventral hippocampal neurogenesis and induced antidepressant-
like behavior.27 Another recent study demonstrated that down-
regulation of NRG1-ErbB4 signaling in parvalbumin interneurons
in the rat brain may contribute to the antidepressant properties of
ketamine.28 In this study, pretreatment with NRG1 abolished both
ketamine's antidepressant effects and ketamine-induced reduc-
tion in p-ErbB4, parvalbumin, 67-kDA isoform of glutamic
acid decarboxylase (GAD67) and gamma-aminobutyric acid levels
and increase in glutamate levels. Our results indicate that genetic
variation in NRG1 may also influence the antidepressant effects
of SSRIs.
Other SSRI-response pharmacogenomics candidate genes aris-
ing from our study, including MCPH1, RYR3, STK39, CTNNA3 and
PPEF2, should be further investigated. Mutations in the human
microcephalin gene MCPH1 cause the autosomal recessive
disorder primary microcephaly, characterized by a congenital
reduction of brain size particularly in the cerebral cortex.29 A
reduction in brain size could result from increased cell death or
alternatively from a diminished self-renewal potential of neuro-
progenitors. A recent report provided evidence that MCPH1
controls neuroprogenitor entry into mitosis.30 Neuroprogenitor
cell proliferation is an early event of neurogenesis, a process by
which new neurons are continuously generated and incorporated
into the nervous system. Recent research has suggested that
hippocampal neurogenesis may have a key role in antidepressant
Table 2. Top clinical outcome association results among the genotyped SNPs in the ISPC sample
Outcome measure SNP CHR BP Nearest gene(s) MA CA MAF C-Frq A-Frq Beta/OR P
%ΔHRSD rs9328202 6 3887339 RPS25P7 A C 0.027 0.04 0.02 0.72 6.15E− 07
rs11989215 8 6395909 ANGPT2/MCPH1 G A 0.360 0.36 0.36 0.24 7.46E− 07
rs16855294 2 169199695 STK39 A C 0.416 0.60 0.32 − 0.24 8.82E− 07
rs7802493 7 138699590 ZC3HAV1L G A 0.010 0.03 0 1.14 9.35E− 07
rs10512361 9 110974998 LOC100128657 G A 0.064 0.18 0 − 0.46 2.61E− 06
rs2453488 12 49255208 RND1/DDX23 A G 0.115 0.27 0.03 − 0.37 3.51E− 06
rs1438692 5 148659664 AFAP1L1 A G 0.491 0.38 0.55 − 0.21 4.42E− 06
rs239022 21 17701594 LINC00478 A G 0.109 0.05 0.14 0.34 4.82E− 06
rs1470108 15 89153744 MIR7-2/MIR3529/MIR1179 A C 0.216 0.35 0.15 − 0.26 6.67E− 06
rs11811628 1 212756393 ATF3 A G 0.013 0.04 0 0.96 7.50E− 06
Response rs11989215 8 6395909 MCPH1/ANGPT2 G A 0.360 0.36 0.36 0.62 6.70E− 06
rs1466882 18 4970506 PPIAP14 C A 0.466 0.52 0.44 1.55 1.23E− 05
rs13015447 2 167377978 SCN7A A C 0.443 0.63 0.35 1.57 1.34E− 05
rs2377898 18 8730053 SOGA2 A G 0.456 0.47 0.45 0.65 1.34E− 05
rs17220479 6 32940815 BRD2 A G 0.055 0.02 0.07 0.34 1.42E− 05
rs16871297 6 32950217 BRD2 G A 0.055 0.02 0.07 0.34 1.42E− 05
rs12729349 1 65570028 MRPS21P1 A G 0.135 0.08 0.16 0.52 2.02E− 05
rs2511398 11 93684809 HPRTP4 G A 0.433 0.56 0.37 1.51 2.28E− 05
rs2218603 2 167472743 SCN7A A G 0.420 0.54 0.36 1.54 3.28E− 05
rs1596996 2 167453461 SCN7A A G 0.452 0.59 0.38 1.53 3.63E− 05
Abbreviations: A-Frq, frequency of MA in Asian subset; Beta/OR, regression parameter estimates (beta) for SNP effect on quantitative trait outcome or odds
ratio (OR) estimate for SNP effect on binary outcome; CA, common allele; C-Frq, frequency of MA in Caucasian subset; HRSD, Hamilton Rating Scale for
Depression; ISPC, International SSRI Pharmacogenomics Consortium; MA, minor allele; MAF, minor allele frequency; SNP, single-nucleotide polymorphism.
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Figure 2. Manhattan plots showing genome-wide association results for the two outcome variables in the meta-analysis of ISPC, AMPS and
STAR*D data. (a) %Δ depression score, (b) response. AMPS, Antidepressant Medication Pharmacogenomics Study; ISPC, International SSRI
Pharmacogenomics Consortium; STAR*D, Sequenced Treatment Alternatives to Relieve Depression.
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action.31,32 A recent genetic study in a Japanese population found
that MCPH1 genetic variation is associated with automatic
thoughts (may be risk factors for depression and anxiety)
evaluated by the Depression and Anxiety Cognition Scale, a
Japanese psychological questionnaire.33 MCPH1 has also been
implicated in autism and schizophrenia.34,35
Ryanodine receptor 3, a protein that in humans is encoded by
the RYR3 gene, is normally enriched in hippocampal area CA1,36
suggesting a specialized role of this receptor in this area critical for
depression and antidepressant action. Ryanodine receptors (RyR)
increase activity-dependent calcium influx via calcium-induced
calcium release. Calcium signals activate postsynaptic pathways in
hippocampal neurons that underlie synaptic plasticity, learning
and memory. Studies suggest that RyR2 and RyR3 isoforms have
key roles in these processes.37,38
The STK39 gene encodes a serine/threonine kinase. The protein
is localized to both the cytoplasm and the nucleus, may act as a
mediator of cell stress response39 and has been implicated in
autism.40 A prior GWAS suggested that genetic variation in
CTNNA3 (catenin alpha 3) is associated with antidepressant
treatment-emergent suicidal ideation.41 Variants in CTNNA3 have
also been suggested to have a role in autism and
schizophrenia.31,42 Finally, PPEF2, a calmodulin-binding protein
phosphatase, has been shown to influence mGluR5 levels and
prior evidence suggests it may be involved in schizophrenia.43
We investigated the association of SSRI response and %ΔHRSD
with SNPs with strongest evidence for association with treatment
outcomes in the two recent large collaborative pharmacoge-
nomics studies of antidepressants.12,13 Consistent with earlier
studies, which have shown difficulties with replication of
pharmacogenomic predictors of antidepressant treatment out-
comes, our analyses did not replicate the prior results, with the
exception of nominal evidence of association for SNP rs11624702
in MDGA2, and rs2546057 in KCTD15. In particular, our analyses
provided nominally significant evidence of association of SNP
rs11624702 in MDGA2 with response in the combined ISPC-AMPS-
STAR*D meta-analysis. Previously, suggestive evidence of
association of this SNP with antidepressant treatment outcomes
was demonstrated in the genome-wide analysis of the NEWMEDS
consortium sample (P= 4.08 × 10−6).13 Other studies have also
implicated this gene in depression-related traits and response to
antidepressants. In particular, a genome-wide association study of
SSRI/SNRI-induced sexual dysfunction in a Japanese cohort
identified 11 MDGA2 SNPs that were significantly associated with
the outcome at a genome-wide significant level.44 Furthermore,
MDGA2 was identified as a potential neuroticism-related gene in a
genome-wide association study,45 a finding that was subsequently
replicated and extended by demonstrating association with a
fatigability and asthenia subscale of harm avoidance.46 Thus,
further investigation of the role of MDGA2 in depression and SSRI-
treatment response is warranted.
Although this study represents one of the largest pharmacoge-
nomics studies of antidepressant response to date, we recognize it
also has certain limitations. Because a variety of SSRIs were used in
the studies contributed to the consortium, this sample provides
the opportunity to identify genes that contribute to the
pharmacodynamic, but not pharmacokinetic, effects of these
medications. Another limitation of the presented analysis is the
short time period of follow-up, as generally, 6–8 weeks is
considered necessary for investigating full response. However, a
4-week period is sufficient for detecting a change in most patients,
and therefore analyses of the 4-week outcomes were focused
solely on relative symptom change and response.
As in all studies of patients with major depression, hetero-
geneity between individual patients likely limits the power of
genetic analyses. Differences in samples across sites, including
differences in the patient populations and treatments, further
increase this phenotypic heterogeneity. Thus, the overall patient
sample is likely to include subgroups with different susceptibility
factors for clinical depression. These might involve endogenous,
neurobiological factors, temporal stress factors and other environ-
mental factors, such as those of cultural or dietary origin.
Investigation of more homogeneous patient subsamples, such
as severe depression or depression with melancholic or
Table 3. Top 10 association regions from the genome-wide association meta-analysis of the combined ISPC+AMPS sample and STAR*D (all race)







% Change in depression
score
rs6889896 5 124699239 LOC644659 − 0.17 − 0.16 − 0.17 5.49E− 07
rs35806662 2 158790425 LOC100130766 − 0.18 − 0.21 − 0.20 6.47E− 07
rs73069924 5 32278233 MTMR12 − 0.50 − 0.42 − 0.44 8.09E− 07
rs4615376 6 13071073 PHACTR1 − 0.20 − 0.13 − 0.16 1.05E− 06
rs2566255 11 4605195 OR52I2/C11orf40 0.24 0.26 0.26 1.51E− 06
rs910039 6 17505944 CAP2 0.10 0.17 0.13 2.11E− 06
rs17068112 6 139250125 REPS1 0.19 0.37 0.26 3.28E− 06
rs7485210 12 131638853 LOC116437 0.18 0.10 0.14 3.42E− 06
rs74378198 5 38870908 OSMR − 0.69 − 0.37 − 0.43 3.77E− 06
rs4236420 7 9688109 PER4 0.10 0.17 0.13 4.08E− 06
Response rs2456568 11 93691332 HPRTP4 1.43 1.29 1.36 5.03E− 08
rs113889867 8 80556500 STMN2 0.67 0.42 0.51 8.68E− 07
rs10954808 8 31479623 NRG1 0.73 0.73 0.73 1.20E− 06
rs506546 1 34439294 CSMD2 0.70 0.83 0.76 1.46E− 06
rs74546197 1 205880179 SLC26A9 0.45 0.47 0.46 3.21E− 06
rs72772787 1 248016378 TRIM58 2.63 1.94 2.34 3.96E− 06
rs2043144 9 73950955 TRPM3 0.33 0.42 0.38 4.30E− 06
rs291028 15 95615786 LOC400456 0.61 0.60 0.61 5.02E− 06
rs7051085 23 23374977 PTCHD1 0.60 0.69 0.63 5.51E− 06
rs1210638 22 18981563 DGCR5 1.34 1.32 1.33 6.04E− 06
Abbreviations: AMPS, Antidepressant Medication Pharmacogenomics Study; Beta/OR, regression parameter estimates (beta) for SNP effect on quantitative trait
outcome or odds ratio (OR) estimate for SNP effect on binary outcome; ISPC, International SSRI Pharmacogenomics Consortium; SNP, single-nucleotide
polymorphism; STAR*D, Sequenced Treatment Alternatives to Relieve Depression. Rather than showing results for multiple SNPs in one region, only one (top)
SNP is shown for each association region. There were other SNPs in these regions with suggesting evidence for association, for example, in the chromosome
11 region near HPRTP4, there were 34 SNPs with Po10−6.
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predominantly anxious features, may lead to additional insights
despite reduced sample sizes. The fact that this study included a
large Asian sample is a strength, as we believe there are no prior
large pharmacogenomics studies of antidepressants in Asian
populations. However, ethnic heterogeneity of the sample may
also have reduced power of our GWA analyses, particularly due to
differences in SNP allele frequencies. The possibility that in
different ethnic populations different SNPs in the same genes may
have functional impact on clinical phenotypes, implies that gene-
level and pathway-level, rather than SNP-level, analyses may be
more powerful in racially diverse samples. Such analyses, as well as
an in-depth investigation of potential differences in genomic
treatment outcome predictors across racial groups, will be the
focus of subsequent publications.
The lack of replicated predictors of treatment response in
published pharmacogenomics studies of antidepressants has
been disappointing, and has prompted questions regarding how
future research in this area should proceed. Recent studies have
demonstrated that very large sample sizes are needed to achieve
the power to identify genetic predictors of complex psychiatric
traits,47 and the same is likely to be true for antidepressant
response. However, other avenues must be explored to increase
power of these studies. A high degree of clinical heterogeneity in
samples of treated patients, as well as the broad definition of
treatment outcomes in most prior pharmacogenomics studies of
antidepressant response, are likely factors contributing to the lack
of significant and replicable findings. Specifically, clinical subtypes
of depression may respond differently to treatment with certain
medications, and medication response may be modified by
different genetic variants for these clinical subtypes. Moreover,
treatment outcomes in pharmacogenomic studies of MDD are
usually limited to overall improvement in depression severity as
measured by scales such as the HRSD. However, specific genes
may impact particular aspects of drug response that contribute to
the total HRSD score (for example, certain types of mood changes,
changes in sleep or appetite/weight and so on). Studies that focus
on more narrowly defined groups of patients, or investigate
specific aspects of treatment response, may thus provide
additional insights into genetic predictors of response to
antidepressants.
In conclusion, the present findings provide little evidence of
specific genetic factors that would markedly affect the clinical
response to SSRI treatment in major depression. Also, similar to
prior efforts, the results of our meta-analyses showed a lack of
robust treatment outcome predictors. Nevertheless, novel biological
targets for further investigation have been identified. In
particular, some of the associations found (such as NRG1 or
MCPH1) might reflect the important role of neuronal renewal
among the mechanisms of antidepressant response.48 There is a
need to replicate the top association signals with larger samples.
There is also a need for closer exploration of genes showing the
most marked associations in more refined and homogeneous
patient subsamples, such as severe depression or depression with
melancholic or predominantly anxious features.
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